NF1-Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of NF1-Mutant Rhabdomyosarcoma and NF1-Associated Malignant Triton Tumor The Prostate Cancer Precision Medicine Multi ...

Nearly half of people diagnosed with advanced cancer over a recent 5-year period did not undergo next-generation sequencing, according to results of a retrospective cohort study.Rates improved over ...

While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma in the community is less consistent. There are disparities in the ...

A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

NGS utilization increased over time but left substantial proportions untested across metastatic breast, prostate, pancreatic, ...

Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center Of the 582 surveys sent, ...

Next-generation sequencing (NGS) allows the simultaneous analysis of multiple genomic alterations with therapeutic implications, paving the way for precision medicine and transforming cancer care.

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased between 2016 and 2021, despite implementation of a recent Medicare national ...

To permanently access this eBook for free, fill out the short form below. Ready to revolutionise your molecular testing for myeloid malignancies? With a constantly expanding list of biomarkers, ...

GMP-qualified NGS adventitious virus detection with a predictable 28-day turnaround and U.S.-based end-to-end support PHILADELPHIA, March 4, 2026 /PRNewswire/ -- Minaris, a global cell and gene ...